Peter Attia, MD
MD (Stanford); former surgeon, Johns Hopkins; longevity physician
Physician focused on the applied science of longevity, founder of Early Medical, author of "Outlive" (2023), and host of The Drive podcast. Within this debate he is a mainstream-leaning reformer: he firmly accepts that ApoB-bearing lipoproteins are causal in atherosclerosis, while arguing that standard LDL-C is an imperfect way to measure the risk.
Position (a lossy summary - the nuance is below)
LDL: benign to causal
+0.70 (strongly toward "LDL causal")
Attia explicitly accepts LDL/ApoB causality - "ApoB is a necessary, though not sufficient, factor in the development of ASCVD" - and criticises influencers who claim LDL does not matter. He is not at the mainstream extreme only because he argues LDL-C is an inferior metric to ApoB.
Statins: anti to pro
+0.60 (toward "Pro-statin")
Supports statins, PCSK9 inhibitors, and ezetimibe for those at moderate-to- high risk and favours early, aggressive ApoB lowering ("longer and lower"), but emphasises individualised, risk-stratified treatment rather than treating by LDL-C alone.
The strongest informed counterweight to the "LDL is irrelevant" camp: he agrees the skeptics ask some right questions (LDL-C alone is insufficient) but reach the wrong conclusion (that atherogenic particles do not matter). His refrain to a metabolically healthy person with high LDL would be: "Great triglyceride/HDL ratio - now I want your ApoB."
Key arguments
- ApoB (particle number) is superior to LDL-C as a risk marker.
- When LDL-C and ApoB are discordant, risk tracks ApoB.
- Discordance is driven by insulin resistance and high triglycerides.
- Cumulative lifetime ApoB exposure matters - lower earlier is better.
Positions on specific claims
- Does LDL cholesterol actually cause heart disease?
Agrees LDL/ApoB is causal; disputes that LDL-C is the right way to measure it.
- Is ApoB a better measure of risk than standard LDL cholesterol?
Strongly endorses ApoB as the superior marker and treatment target.
Conflicts of interest
Commercial: paid subscription media (The Drive), book sales ("Outlive"), and a concierge medical practice. No pharmaceutical funding disclosed here; treats patients with lipid-lowering drugs.
Fair criticisms
- Critics on the skeptic side argue his ApoB-lowering targets (<60, ideally <40 mg/dL) extrapolate beyond direct trial evidence in low-risk people.